Corona Remedies IPO news: Pharma company Corona Remedies made a strong start in the stock market on Monday. The shares were listed at a 38.42% premium over the IPO price of ₹1,062, showing high investor interest.
The stock is now trading on both the NSE and BSE. Around 11:11 AM, Corona Remedies shares were trading at about ₹1,470 on NSE and ₹1,473 on BSE.
Corona Remedies IPO gets strong response
The ₹655 crore Corona Remedies IPO received a huge response from investors. The issue was subscribed 144.5 times in total. Big investors showed the most interest, with Qualified Institutional Buyers subscribing nearly 294 times. Non institutional investors subscribed over 220 times and retail investors also participated so well.
This strong demand shows confidence in the company’s business, products & future growth.
Also Read: PM Kisan 22nd Instalment Coming Soon? Big Update on Payment Date & e-KYC
No fresh funds raised in Corona Remedies IPO
The Corona Remedies IPO was completely an offer for sale, which means the company did not raise new money. All the IPO proceeds went to the selling shareholders. The company entered the stock market with a strong balance sheet and a history of regular profits.
Based on the IPO price, Corona Remedies market value is around ₹6,495 crore.The valuation is on the higher side but investors are ready to pay a premium due to steady growth and the good profit margins.
Strong financial performance
Corona Remedies has shown good financial growth. In FY25, the company revenue increased 18% to ₹1,202 crore, while profit after tax jumped 65% to ₹149 crore. In June 2025 quarter company reported a profit of ₹46 crore showing continue growth. The company also show has strong return ratios with ROE of 27.5% & ROCE above 41% along with low debt.
Anchor investors support Corona Remedies IPO
Before the IPO opened anchor investors invested around ₹195 crore. Their participation increased confidence among other investors and helped boost demand during the public issue.
About Corona Remedies
Corona Remedies focuses on important treatment areas such as women’s healthcare, heart care, pain management & urology. The company operates in 22 states and has more than 2,600 medical representatives, giving it a strong presence across India.
1 thought on “Corona Remedies IPO: Stock Lists at 38% Premium, Makes Strong Dalal Street Debut”